Simulations Plus, Inc. (NASDAQ:SLP) Receives $49.40 Consensus PT from Brokerages

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been assigned an average rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $49.40.

SLP has been the subject of several recent analyst reports. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Stephens began coverage on Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp raised their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Finally, BTIG Research dropped their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 19.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Simulations Plus

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. First Horizon Advisors Inc. raised its stake in shares of Simulations Plus by 82.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after acquiring an additional 370 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Simulations Plus by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after purchasing an additional 456 shares during the last quarter. Pitcairn Co. raised its position in shares of Simulations Plus by 9.1% in the third quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after purchasing an additional 549 shares during the period. US Bancorp DE lifted its stake in shares of Simulations Plus by 14.3% in the fourth quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock worth $159,000 after buying an additional 713 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Simulations Plus by 7.6% in the third quarter. Franklin Resources Inc. now owns 10,797 shares of the technology company’s stock worth $342,000 after buying an additional 766 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Stock Performance

Simulations Plus stock opened at $36.19 on Friday. Simulations Plus has a 52 week low of $24.00 and a 52 week high of $51.22. The firm has a market capitalization of $727.13 million, a price-to-earnings ratio of 90.48 and a beta of 0.83. The company has a 50 day moving average price of $30.56 and a 200 day moving average price of $32.42.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.